documents

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

5 rows where docket_id = "FDA-2005-P-0124" sorted by posted_date descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: title, subtype, posted_date, posted_month, posted_date (date), comment_start_date (date), last_modified (date)

posted_year 2

document_type 2

agency_id 1

id agency_id docket_id title document_type subtype posted_date ▲ posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2005-P-0124-0005 FDA Re-Listing Petition to determine that two strenghths, 50 mg and 250 mg lamotrigene oral tablets, were not withdrawn due to safety nor efficacy concerns FDA-2005-P-0124 Letter from FDA CDER to Pharmaceutical Patent Attorneys Other LET-Letter 2007-03-19T04:00:00Z 2007 3     2024-12-13T15:36:22Z   0 0 090000648043fc3f
FDA-2005-P-0124-0004 FDA Re-Listing Petition to determine that two strenghths, 50 mg and 250 mg lamotrigene oral tablets, were not withdrawn due to safety nor efficacy concerns FDA-2005-P-0124 Determination That LAMICTAL (Lamotrigine) Tablets, 50 Milligrams and 250 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness Notice N-Notice 2007-03-05T05:00:00Z 2007 3 2007-03-02T05:00:00Z   2024-12-13T15:35:05Z   0 0 090000648043fc3e
FDA-2005-P-0124-0003 FDA Re-Listing Petition to determine that two strenghths, 50 mg and 250 mg lamotrigene oral tablets, were not withdrawn due to safety nor efficacy concerns FDA-2005-P-0124 Letter from FDA CDER to Pharmaceutical Patent Attorneys, LLC Other LET-Letter 2005-12-16T05:00:00Z 2005 12     2024-12-13T15:34:04Z   0 0 090000648043fc3d
FDA-2005-P-0124-0002 FDA Re-Listing Petition to determine that two strenghths, 50 mg and 250 mg lamotrigene oral tablets, were not withdrawn due to safety nor efficacy concerns FDA-2005-P-0124 Acknowledgment Letter from FDA DDM to Pharmaceutical Patent Attorneys, LLC Other Acknowledgement Letter/Receipt 2005-06-16T04:00:00Z 2005 6     2024-12-13T15:32:45Z   0 0 090000648043fc3c
FDA-2005-P-0124-0001 FDA Re-Listing Petition to determine that two strenghths, 50 mg and 250 mg lamotrigene oral tablets, were not withdrawn due to safety nor efficacy concerns FDA-2005-P-0124 Acknowledgment Letter from FDA DDM to Pharmaceutical Patent Attorneys, LLC Other Acknowledgement Letter/Receipt 2005-06-16T04:00:00Z 2005 6     2024-12-13T15:31:35Z   0 0 090000648043fc2d

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options: 

CREATE TABLE documents (
    id TEXT PRIMARY KEY,
    agency_id TEXT,
    docket_id TEXT REFERENCES dockets(id),
    title TEXT,
    document_type TEXT,
    subtype TEXT,
    posted_date TEXT,
    posted_year INTEGER,
    posted_month INTEGER,
    comment_start_date TEXT,
    comment_end_date TEXT,
    last_modified TEXT,
    fr_doc_num TEXT,
    open_for_comment INTEGER,
    withdrawn INTEGER,
    object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);